# Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

> **NCT05776173** · NA · RECRUITING · sponsor: **Shanghai BDgene Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- β-thalassemia Major

## Interventions

- **GENETIC:** BD211

## Key facts

- **NCT ID:** NCT05776173
- **Lead sponsor:** Shanghai BDgene Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2026-03
- **Final completion:** 2026-10
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776173, "Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05776173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*